Skip to main content

Table 2 Characterization of NPs

From: Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

 

Size (nm)

Zeta (mV)

PDI

DEE (%)

DLC (%)

Blank-NPs

106.70 ± 1.72

−32.9 ± 1.23

0.104 ± 0.015

–

–

LFC-Blank-NPs

124.30 ± 2.22

−14.80 ± 2.06

0.120 ± 0.022

–

–

Sora-NPs

112.37 ± 2.89

−33.13 ± 1.17

0.106 ± 0.027

54.82 ± 6.46

1.09 ± 0.13

LFC-Sora-NPs

145.10 ± 2.08

−15.47 ± 2.44

0.113 ± 0.012

52.17 ± 3.92

1.03 ± 0.07

Meta-NPs

114.80 ± 2.70

−32.80 ± 2.40

0.135 ± 0.030

63.31 ± 12.75

1.27 ± 0.27

LFC-Meta-NPs

147.10 ± 0.92

−17.80 ± 1.41

0.123 ± 0.065

61.34 ± 19.40

1.23 ± 0.34

  1. Data are expressed as the mean ± SD (n = 3)